The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I always found Munch’s wife drops her knickers plenty quick ;)
No.
That was quick
I also swing both ways as you know... been in and (not very often out) of TXP since 8.5p not long after listing.
Dana comes out as truly bi-oily.
Historic day.
and all this time we are making money, adding to the cash pile... which is twice the mcap :)
I've heard the same repeatedly from a nurse friend... they have had lots of negatives that they are 100% convinced are false as the subjects show clear symptoms. She reckons they are cracking on for 50% false negs.
Amazon will screw you into the ground if they sell your product direct (as in 'sold by Amazon') ... I've had brands they have wanted to 'buy' direct and they want so much of the pie it is not economically viable without a massive hike in RRP.
Amazon FBA is different ... you send the product, they take a warehouse and pick & pack fee plus postage and a sales commission on top (say 15%)... Medusa19 could still use that route via Amazon so the product is still available on the platform globally.... if they feel it is necessary.
So perhaps folks can stop suggesting that we should've gone for distribution via bleed you dry Amazon instead of the obviously very capable Boohoo crew who are also aligned shareholders.
I wasn't convinced on first read tbh... a bit on the jobs for the boys side.
That said... I expect that any global distribution via an established major pharma route would be extremely punitive on margin to Avacta which combined with manufacturing farmed out to Cytiva would squeeze profits and increase the price of the test. It's not like this is a product that would need much 'marketing' to get word out convince consumers to buy it. In this day and age and given the reality of the C19 situation it may not actually be out of the way to go more direct using experienced online global retail distribution channels that are not 'big pharma'... especially when that distribution is aligned with shareholders.
It's the manufacturing process and scale that is most important to have well connected with big pharma and that we have covered with Cytiva of course.
Cheeky **** drop on open that ... drop it 14% with a 14% spread :)
Better control of risk with those options, was pointing that out to a very clever friend of mine recently. Beware though Dana, taking options can lead to harder stuff ;)
ideal environment for Rockrose atm
soon gap up when oil's flirtng with $100 :)